Jonathan Angel
MD, FRCPC
Senior Scientist, Inflammation and Chronic Disease
Ottawa Hospital Research Institute
Professor, Department of Biochemistry
Microbiology and Immunology
Professor, Department of Medicine
Faculty of Medicine
Research Groups
Angel HIV Lab
Bio
Dr. Angel graduated from medical school at the University of Toronto in 1988, which was followed by an internal medicine residency in Toronto. After one year as the chief medical resident at St. Paul's Hospital in Vancouver, he did his clinical and research infectious diseases training at the New England Medical Center/Tufts University in Boston. In 1995, Dr. Angel joined the Division of Infectious Diseases, Department of Medicine at the Ottawa General Hospital. Since that time he has been involved in laboratory based and clinical research as well as teaching and patient care. His research is focused on understanding how HIV damages the immune system and how these insights can potentially lead to new therapies. Dr. Angel is currently a Professor of Medicine at the University of Ottawa, and a Senior Scientist in the Ottawa Hospital Research Institute.
News
Publications
Thigh Injections of Cabotegravir + Rilpivirine in Virally Suppressed Adults With HIV-1: A Substudy of the Phase 3b ATLAS-2M Study
2025-08-01 Go to publicationFailure of γδ T Cell Recovery in the Gut With Effective Anti‐HIV Therapy
2025-01-01 Go to publicationLentiviral Infections Persist in Brain despite Effective Antiretroviral Therapy and Neuroimmune Activation
2021-12-21 Go to publicationIntravenous administration of Penicillin results in therapeutic intravitreal levels in chronic postoperative endophthalmitis
2021-12-01 Go to publicationCurrent
CIHR (2020 - 2025)
“Use of antimicrobial peptides, LL-37/17BIPHE2, as vaginal spermicides/microbicides as part of multipurpose prevention technology (MPT)”
Principal Investigators: N. Tanphaichitr, J.B. Angel, S. Gadde, P.M. Sheth
CIHR (2024-2025)
“HIV Vaccines: Search for a Cure”
Principal Investigator: J.B. Angel
Co-Investigator: M.D. Grant
CIHR (2024 - 2029)
“CIHR Pan-Canadian Network for HIV/AIDS and Sexually Transmitted and Blood Borne Infections (STBBI) Clinical Trials Research (CTN)”
Principal Investigators: M.B. Klein, M. Habanyama, E. Mandarino, C. Martin, J.B. Angel, et al.
CIHR (2025 - 2029)
“Canadian HIV Cure Enterprise 3.0: Targeting tissue HIV reservoirs”
Principal Investigators: E.A. Cohen, J.B. Angel, N. Chomont, T.T. Murooka, P. Ancuta, et al.
Select Previously Held
CIHR (2009 - 2014)
"Regulation of IL-12 family of TH1 cytokines IL-12, IL-23 and IL-27 by HIV"
Principal Investigators: J.B. Angel and A. Kumar
CIHR (2012 - 2017)
"Regulation and function of soluble IL-7 receptor alpha (CD127) in HIV infection"
Principal Investigator: J.B. Angel
CIHR (2014 - 2018)
"The Canadian HIV Cure Enterprise (CanCURE)"
Principal Investigators: E. A. Cohen, P. Ancuta, J.B. Angel, J-P Routy, K.R. Fowke et al.
CIHR (2014 - 2018)
"Antimicrobial host defense peptides: their potential use as vaginal contraceptives with anti-HIV properties"
Principal Investigators: N. Tanphaichitr and J.B. Angel
CIHR (2019 - 2024)
“Canadian HIV Cure Enterprise 2.0: Targeting the interplay between myeloid cells and CD4+ T-cells for HIV cure”
Principal Investigators: E.A. Cohen, J.B. Angel, N. Chomont, T.T. Murooka, P. Ancuta, et al.